What is the primary objective of NIS2?

The primary objective of NIS2 is to establish a high common level of cybersecurity and resilience across EU member states by strengthening critical infrastructure and digital services against cyber threats. NIS2, or Directive (EU) 2022/2555, expands on the original NIS Directive with a size-cap rule applying to medium and large entities in sectors like energy, transport, health, digital infrastructure, public administration, postal services, waste management, and food production. It mandates proactive risk management, including ongoing risk assessments, supply chain security, incident response, access controls, encryption, and business continuity plans, while enforcing strict incident reporting—early warning within 24 hours, detailed notification within 72 hours, and final report within one month—to national CSIRTs.

Who is legally or professionally required to comply with NIS2?

NIS2 applies to all medium-sized and large entities classified as 'essential' or 'important' within specified high-criticality sectors across EU member states. Essential entities typically have 250+ employees, €50M+ annual turnover, or €43M+ balance sheet; important entities have 50+ employees, €10M+ annual turnover, or €10M+ balance sheet, though criticality of service can override size thresholds for sole providers. Covered sectors include energy (electricity, oil, gas, district heating, hydrogen), transport, banking, health, manufacturing, digital providers (cloud computing, online marketplaces), and public administration. EU member states transposed NIS2 into national law by October 17, 2024, with entities required to register with central authorities providing details like name, contacts, sector, and operating states.

Does NIS2 require an external audit or third-party certification?

NIS2 does not mandate external audits or third-party certification but empowers national authorities to conduct live spot checks and demand real-time evidence of compliance. It shifts from static "box-ticking" to continuous assurance, requiring entities to maintain dynamic risk registers, OT/IT asset inventories, supply chain oversight, and verifiable trails of risk assessments, incident responses, training, and mitigations like encryption and access controls. Senior management bears direct accountability, with authorities able to verify controls on-demand post-transposition since October 18, 2024.

How often should an assessment for NIS2 be performed?

NIS2 requires continuous risk assessments with dynamic updates, such as quarterly reviews of risk registers and asset inventories, rather than fixed annual cycles. Entities must maintain ongoing, evidence-based practices covering supply chain risks, vulnerability management, incident detection, and business continuity, supporting real-time spot checks by national authorities and CSIRTs. This aligns with the directive's emphasis on proactive resilience since transposition deadlines in October 2024.

What are the consequences of non-compliance with NIS2?

Non-compliance with NIS2 incurs tiered fines up to €10 million or 2% of total global annual turnover for essential entities and €7 million or 1.4% for important entities, plus potential business suspension and personal liability for senior management. Enforcement by national authorities includes spot checks, remedial orders, and naming/shaming, effective post-October 18, 2024, transposition, with stricter penalties reflecting heightened board-level accountability.

Can NIS2 be mapped to other international frameworks?

Yes, EU member states incorporate standards like ISO 27001, NIST CSF, and ENISA guidelines into national NIS2 frameworks to facilitate mapping and compliance. Organizations leverage these for risk management, incident reporting, and supply chain controls, aligning NIS2's continuous assurance model with established practices while tailoring to sector-specific requirements like energy OT/IT security.

What is the first step to begin implementing NIS2?

The first step to implement NIS2 is to determine applicability by assessing entity size, sector, and operations against the size-cap rule and criticality thresholds. Conduct a gap analysis of current risk management, register with national authorities if covered, and prioritize dynamic risk assessments, incident reporting procedures (24/72-hour timelines), supply chain reviews, and board-level governance for ongoing post-October 2024 enforcement.

What is the primary objective of FDA 21 CFR Part 11?

The primary objective of FDA 21 CFR Part 11 is to establish criteria under which the Agency considers electronic records and electronic signatures trustworthy, reliable, and equivalent to paper records and handwritten signatures executed on paper (§11.1(a)). This equivalency enables electronic methods while ensuring authenticity, integrity, availability, and non-repudiation through controls for closed (§11.10) and open systems (§11.30), plus electronic signature requirements (Subparts B and C).

Who is legally or professionally required to comply with FDA 21 CFR Part 11?

FDA 21 CFR Part 11 applies to organizations using electronic records created, modified, maintained, archived, retrieved, or transmitted under predicate rules, or electronic records/signatures relied upon for regulated activities (§11.1(b)). This includes pharmaceutical, biotech, medical device, and CRO/CMO firms where electronic records replace paper for predicate-required records (e.g., 21 CFR 211, 820) or are submitted to FDA under docket 92S-0251.

Does FDA 21 CFR Part 11 require an external audit or third-party certification?

No, FDA 21 CFR Part 11 does not require external audits or third-party certification. Compliance is demonstrated through internal validation, SOPs, and inspection readiness (§11.1(e)), with systems, controls, and documentation readily available for FDA review. FDA's 2003 guidance emphasizes risk-based approaches without mandating external validation.

How often should an assessment for FDA 21 CFR Part 11 be performed?

FDA 21 CFR Part 11 does not prescribe a fixed frequency for assessments; they must occur via change control, periodic reviews, and risk-based revalidation to ensure ongoing fitness for use. Integrate into quality systems for system changes (§11.10(k)), operational checks (§11.10(f)), and predicate rule compliance, with periodic audit trail reviews and access audits recommended per SOPs.

What are the consequences of non-compliance with FDA 21 CFR Part 11?

Non-compliance with FDA 21 CFR Part 11 can result in FDA enforcement actions including Form 483 observations, warning letters, product holds, recalls, and fines under predicate rules. FDA enforces core controls (e.g., access, signatures) and predicate requirements despite discretion on some elements; data integrity failures often lead to CGMP violations and injunctions.

Can FDA 21 CFR Part 11 be mapped to other international frameworks?

FDA 21 CFR Part 11 is not explicitly mapped to other frameworks within its text or 2003 guidance, focusing solely on FDA predicate rules. Organizations may align controls risk-based but must prioritize Part 11 criteria for U.S. compliance.

What is the first step to begin implementing FDA 21 CFR Part 11?

The first step to implement FDA 21 CFR Part 11 is to establish a formal applicability framework mapping predicate rules to records and documenting reliance decisions (electronic vs. paper) in SOPs or specifications. Per 2003 guidance, classify systems as closed/open and prioritize enforced controls like access (§11.10(d)) and signatures (§11.100).

Standards Comparison

NIS2 vs FDA 21 CFR Part 11

NIS2

Mandatory

2022

EU regulation enhancing cybersecurity resilience for critical sectors

FDA 21 CFR Part 11

Mandatory

1997

FDA regulation for trustworthy electronic records and signatures.

Quick Verdict

NIS2 mandates EU-wide cybersecurity resilience for critical infrastructure, while FDA 21 CFR Part 11 ensures electronic records' trustworthiness in life sciences. Companies adopt NIS2 for regulatory survival in essential sectors; Part 11 for compliant digital transformation and FDA inspection readiness.

Cybersecurity

NIS2

Directive (EU) 2022/2555 Network and Information Systems 2

Cost

€€€€

Complexity

Medium

Implementation Time

12-18 months

Key Features

Broadened scope via size-cap rule for medium/large entities
Strict multi-stage incident reporting timelines
Direct senior management accountability for compliance
Continuous proactive risk management framework
Fines up to 2% global annual turnover

Electronic Records

FDA 21 CFR Part 11

21 CFR Part 11 Electronic Records; Electronic Signatures

Cost

€€€€

Complexity

Medium

Implementation Time

18-24 months

Key Features

Secure, time-stamped audit trails for changes
Controls for closed and open systems
Electronic signatures equivalent to handwritten
Risk-based system validation requirements
Access, authority, and device checks

Detailed Analysis

A comprehensive look at the specific requirements, scope, and impact of each standard.

NIS2 Details

What It Is

NIS2, officially Directive (EU) 2022/2555, is an EU regulation expanding the original NIS Directive. It establishes a high common level of cybersecurity resilience for critical infrastructure and digital services across member states. NIS2 employs a risk-based, continuous assurance approach, shifting from static compliance to proactive, evidence-based practices.

Key Components

Four pillars: risk management, business continuity, incident reporting, corporate accountability.
Mandates robust measures like supply chain security, access controls, encryption, and incident response plans.
Strict reporting: 24-hour early warning, 72-hour notification, one-month final report to CSIRTs.
Aligns with standards like ISO 27001, NIST; enforced via national audits and spot checks, no formal certification.

Why Organizations Use It

Essential/important entities comply to avoid fines up to 2% global turnover or €10M. It enhances cyber resilience, mitigates threats, ensures business continuity, and builds stakeholder trust. Provides competitive advantages through harmonized multi-state operations and proactive defense.

Implementation Overview

Applies to medium/large entities in sectors like energy, transport, digital services via size-cap rule. Involves risk assessments, governance setup, training, and supplier oversight. Member states transposed by October 2024; requires ongoing monitoring and real-time evidence for authorities. (178 words)

FDA 21 CFR Part 11 Details

What It Is

FDA 21 CFR Part 11 is a U.S. federal regulation establishing criteria for electronic records and electronic signatures to be considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. It applies to FDA-regulated industries using electronic systems for predicate rule records, employing a risk-based approach with controls for closed and open systems.

Key Components

Subparts covering general provisions, electronic records (§11.10 closed systems, §11.30 open systems), and signatures (§§11.50-11.300).
Core controls: validation, audit trails, access limits, operational/authority/device checks, training, accountability policies.
Built on ALCOA+ principles; no formal certification, but FDA enforcement and inspections.

Why Organizations Use It

Mandatory for electronic reliance in pharma, devices, biotech to avoid enforcement.
Enhances data integrity, inspection readiness, operational efficiency.
Mitigates risks like warning letters; builds stakeholder trust.

Implementation Overview

Phased: scoping, gap analysis, validation (IQ/OQ/PQ), SOPs, training.
Targets life sciences; global via harmonization; FDA inspections verify compliance.

Key Differences

Aspect	NIS2	FDA 21 CFR Part 11
Scope	Cybersecurity risk management, incident reporting, resilience for critical sectors	Electronic records/signatures trustworthiness, system controls for FDA-regulated records
Industry	Essential/important entities in EU sectors (energy, transport, digital services)	Life sciences (pharma, devices, biotech) using electronic records under FDA predicate rules
Nature	Mandatory EU directive, transposed nationally with enforcement authorities	US FDA regulation with enforcement discretion on some controls, predicate rules enforced
Testing	Risk assessments, continuous assurance, spot checks by national authorities	Risk-based system validation (IQ/OQ/PQ), audit trails, access controls testing
Penalties	Up to 2% global turnover or €10M for essential entities	Warning letters, Form 483s, product holds, injunctions for data integrity failures

Scope

NIS2

Cybersecurity risk management, incident reporting, resilience for critical sectors

FDA 21 CFR Part 11

Electronic records/signatures trustworthiness, system controls for FDA-regulated records

Industry

NIS2

Essential/important entities in EU sectors (energy, transport, digital services)

FDA 21 CFR Part 11

Life sciences (pharma, devices, biotech) using electronic records under FDA predicate rules

Nature

NIS2

Mandatory EU directive, transposed nationally with enforcement authorities

FDA 21 CFR Part 11

US FDA regulation with enforcement discretion on some controls, predicate rules enforced

Testing

NIS2

Risk assessments, continuous assurance, spot checks by national authorities

FDA 21 CFR Part 11

Risk-based system validation (IQ/OQ/PQ), audit trails, access controls testing

Penalties

NIS2

Up to 2% global turnover or €10M for essential entities

FDA 21 CFR Part 11

Warning letters, Form 483s, product holds, injunctions for data integrity failures

Frequently Asked Questions

Common questions about NIS2 and FDA 21 CFR Part 11

NIS2 FAQ

FDA 21 CFR Part 11 FAQ

You Might also be Interested in These Articles...

Your Compliance Command Center: How Modern Tools Orchestrate Cross-Departmental Adherence

Unlock your compliance command center with modern tools for real-time monitoring, automation & integrations across IT, HR, Legal & Finance. Slash non-compliance

SOC 2 Trust Services Criteria in Plain English: Side-by-Side Decoder for Security, Availability, and Beyond

Decode AICPA Trust Services Criteria from auditor jargon to plain English with side-by-side tables, analogies & TL;DRs. CISOs & founders: implement SOC 2 contro

NIST CSF 2.0 Govern Function Deep Dive: Building Executive Cybersecurity Governance from Scratch

Step-by-step blueprint for NIST CSF 2.0 Govern function: templates, RACI matrices, metrics to elevate cybersecurity governance to boardroom level. Reduce breach

Run Maturity Assessments with GRADUM

Transform your compliance journey with our AI-powered assessment platform

Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

100+ Standards & Regulations

AI-Powered Insights

Collaborative Assessments

Actionable Recommendations

Explore More Comparisons

See how NIS2 and FDA 21 CFR Part 11 compare against other standards

Other NIS2 Comparisons

Other FDA 21 CFR Part 11 Comparisons

Quick Verdict

What It Is

Key Components

Four pillars: risk management, business continuity, incident reporting, corporate accountability.

Mandates robust measures like supply chain security, access controls, encryption, and incident response plans.

Strict reporting: 24-hour early warning, 72-hour notification, one-month final report to CSIRTs.

Aligns with standards like ISO 27001, NIST; enforced via national audits and spot checks, no formal certification.

Implementation Overview

What It Is

Key Components

Subparts covering general provisions, electronic records (§11.10 closed systems, §11.30 open systems), and signatures (§§11.50-11.300).

Core controls: validation, audit trails, access limits, operational/authority/device checks, training, accountability policies.

Built on ALCOA+ principles; no formal certification, but FDA enforcement and inspections.

Aspect

NIS2

FDA 21 CFR Part 11

Scope

Cybersecurity risk management, incident reporting, resilience for critical sectors

Electronic records/signatures trustworthiness, system controls for FDA-regulated records

Industry

Essential/important entities in EU sectors (energy, transport, digital services)

Life sciences (pharma, devices, biotech) using electronic records under FDA predicate rules

Nature

Mandatory EU directive, transposed nationally with enforcement authorities

US FDA regulation with enforcement discretion on some controls, predicate rules enforced

Testing

Risk assessments, continuous assurance, spot checks by national authorities

Risk-based system validation (IQ/OQ/PQ), audit trails, access controls testing

Penalties

Up to 2% global turnover or €10M for essential entities

Warning letters, Form 483s, product holds, injunctions for data integrity failures